Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2001

View Archived Issues

New therapeutic areas unfold for galantamine

NeoPharm seeks orphan drug status for IL-13-PE38

Atrix licenses novel growth-promoting peptide from Tulane

Pump therapy with insulin aspart approved by EMEA

Antifibrotic compounds the focus of a FibroGen/Sankyo collaboration

Nonfeminizing estrogen targeting neurodegenerative diseases completes phase I

Novel chelator designed by D-Pharm commences phase II clinical development for stroke

DB-289 enters phase II trials in Africa for trypanosomiasis

Oralin is a suitable substitute for injected insulin according to EASD presentations

Intercalating agent may be useful in MS; preclinical data presented at ECTRIMS 2001

Increase in ACh efflux may underlie cognition-improving effects of atypical antipsychotics

FDA requires further information for approval of Plenaxis

Evidence presented in Nice supports lavender aromatherapy in dementia-associated agitation

Novartis launches NAVIGATOR trial for diabetes and cardiovascular disease prevention

Stimulation of exocytosis from pancreatic beta-cells by imidazolines is PLA2-dependent

Cell Pathways completes phase I study of Aptosyn/Taxotere combination regimen, phase II begins

New glucose transport stimulator under study at Korean centers

Epimmune updates HIV vaccine program

First clinical data on peptide for autoimmune diabetes presented during EASD meeting

Promising preclinical results reported for Cel-Sci's HIV immunotherapeutic

Phase I rhASB trial successfully meets its primary objective

Rituximab now available in Japan

Urotensin-II receptor antagonists discovered by GSK team

Boehringer Ingelheim reports new piperazine MTP inhibitors

Antithrombotic benzimidazoles in early research at Boehringer Ingelheim

Joint research at Karo Bio and Abbott leads to liver-selective GR antagonists

Subtype-selective nAChR ligands designed at British university

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...